|
GSK PLC on Thursday gave an update on its investigational targeted inhibitor linerixibat as a treatment for relentless itch. The London-based pharmaceutical company said in a phase 3 trial, primary and key secondary endpoints were met, which demonstrated a ‘rapid, significant and sustained improvement’ in cholestatic pruritus, also known as relentless itch, and itch-related sleep interference, compared to a placebo. ‘Monthly itch score evaluated the worst weekly itch of each month over the 24-week treatment period. This finding supports linerixibat’s potential to address a major symptom of PBC, relentless itch,’ GSK said. PBC, or primary biliary cholangitis, is a rare autoimmune liver disease. Linerixibat is an investigational targeted inhibitor of the ileal bile acid transporter. It is currently not approved anywhere in the world. ‘Relentless itch is present in the majority of patients with PBC and is a symptom that affects sleep, mental health, and quality of life. With linerixibat, we are one step closer to addressing the high unmet need of itch and its related sleep interference that are critically important to patients but historically under-treated,’ said Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, at GSK. GSK shares were 0.1% lower at 1,377.72 pence each on Thursday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
